Brian Park, PharmD

To address the ongoing COVID-19 related iodinated contrast media product shortage, Iomeron will be temporarily available in the US starting at the end of August 2022.

The designation was based on data from 2 phase 2 proof-of-concept studies that evaluated VX-548 for acute pain following abdominoplasty or bunionectomy surgery.

A 50 mcg booster dose of mRNA-1273.214 elicited significantly higher neutralizing antibody responses against Omicron subvariants BA.4 and BA.5 in adults.

First Relief is a wearable PENS device that is placed behind the ear.

PLG0206 is an investigational, broad-spectrum, anti-biofilm, anti-infective peptide therapeutic.

The expanded approval was based on data from the phase 4 MIRROR trial, which evaluated Krystexxa plus methotrexate in 152 adults with uncontrolled gout.

RoxyBond is an abuse-deterrent formulation of immediate-release oxycodone that features a unique abuse-deterrent technology.

Patients prescribed the 30 mg dose who receive the 60 mg dose may potentially be at risk for overdose and death.

Pharmacodynamic studies have shown that nalmefene has a longer duration of action than naloxone.

Eplontersen is an investigational ligand-conjugated antisense medicine designed to reduce the production of TTR protein to treat both hereditary and nonhereditary forms of ATTR.